The CHS / Pfizer Care Until Cure Research Program

This program allows Canadian investigators to conduct research on medical and psychosocial aspects of bleeding disorders, including outcome evaluation. Grants are awarded for clinical research in fields relevant to improving the quality of life for persons with hemophilia, persons with von Willebrand disease or other inherited bleeding disorders, persons with related conditions such as HIV or hepatitis C, and carriers of an inherited bleeding disorder.

For the 2018-2019 granting period of the program, specific areas of interest have been identified and investigators are encouraged to submit proposals within these areas. The grants review committee will allocate funding to the strongest and most relevant projects included but not limited to the areas of interest listed below.

2018-2019 AREAS OF INTEREST include and are not limited to:

  • Hemophilia B

1. Epidemiology / burden of disease / outcome research
2. Routine prophylaxis and preventative treatment
3. Surgical prophylaxis, dosing
4. Pharmacokinetics (including recovery) in Hem B
5. Joint outcomes and optimizing therapy
6. The role of non-circulating & extravascular Factor IX in hemostasis
7. Mild Hemophilia B: clinical outcomes, healthcare utilization, joint surveillance
8. “Real World” Observational Data on Factor Utilization & Cost-effectiveness

  • Transition and clinical issues

    1. Treatment adherence to prescribed regimens
    2. Management of adolescent hemophilia patients
    3. Management of aging hemophilia population
    4. Tailoring/Personalized Hemophilia Treatment (eg, pharmacokinetics and other factors)

    • Clinical monitoring of hemophilia treatment

    1. Inhibitors, Inhibitor Management (eg, Immune tolerance), and Immunogenicity
    2. The role of point-of-care joint ultrasonography in the management of Hemophilia

    • Product switching experience

    1. Rationale for switching products
    2. Inhibitor development and safety associated with switches
    3. Understanding differences in Factor VIII molecules (eg, full-length versus B-domain deleted)

    • Antifibrinolytic Therapy

    For the CHS / Pfizer Care Until Cure Research Program, individual grants valued at $75,000 per year will be awarded to researchers for a maximum of $150,000 which can be expended over 2 or 3 years. If a two year award is provided, the second year of funding is dependent on evidence of progress as described in the required progress report. Grant funding will begin on April 1, 2018.


    Agency Name: 
    Canadian Hemophilia Society
    Contact Name: 
    Penny D'Agnone
    Grant Amount: 
    $75,000 per year up to a maximum of $150,000 over 2 or 3 years.
    Grant Location: 
    External Deadline: 
    Wednesday, November 15, 2017
    Grant Type: 
    Grant Area: 
    Natural Science
    Grant Eligibility: